Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment.
about
How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA studyUse of Vildagliptin in Management of Type 2 Diabetes: Effectiveness, Treatment Persistence and Safety from the 2-Year Real-Life VILDA StudyPotential glycemic overtreatment in patients ≥75 years with type 2 diabetes mellitus and renal disease: experience from the observational OREDIA study.Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database.Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial.Impact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy of vildagliptin.Predictive clinical parameters and glycemic efficacy of vildagliptin treatment in korean subjects with type 2 diabetes.Experience with Vildagliptin in Type 2 Diabetic Patients Fasting During Ramadan in France: Insights from the VERDI Study.Experience with vildagliptin in patients ≥75 years with type 2 diabetes and moderate or severe renal impairment.Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment.Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patientsIs There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease?
P2860
Q33779315-000DFC1B-BBA4-45B6-A72A-C340F71480B0Q33785141-06629A9D-D44B-4E11-A022-3A2FCDE9B637Q35841565-A1952837-B38C-41F6-9778-9133C36F44DCQ35887463-42C8BEA6-1BEC-44A5-A8CF-45314705BD60Q35921498-F313B22C-79EF-4846-A73B-4F5074B3AE9BQ36428052-E5094847-2EB2-41E7-A48A-185062E5EE02Q36628919-4283F36B-0344-4416-930A-921B33AF3C36Q37468458-13CAFDF1-8332-4AE5-8EA1-A76E6CCC09CEQ37468480-93A537DA-2B40-4B23-B659-A77D26888406Q38107347-DAE4C139-7EBD-42CE-894D-4B9189F0403BQ38378906-A2C03223-A9FC-4953-8C5B-0610274E505FQ38452890-EBFF4702-670B-4D2C-995C-E0AB7A660D59Q41856389-FB7DF14A-E58D-4C89-B87D-A1A0D7888140
P2860
Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Incretin therapies in the mana ...... mellitus and renal impairment.
@en
type
label
Incretin therapies in the mana ...... mellitus and renal impairment.
@en
prefLabel
Incretin therapies in the mana ...... mellitus and renal impairment.
@en
P2860
P356
P1433
P1476
Incretin therapies in the mana ...... mellitus and renal impairment.
@en
P2093
Anja Schweizer
Sylvie Dejager
P2860
P356
10.3810/HP.2012.04.965
P407
P577
2012-04-01T00:00:00Z